We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based biotechnology company Amgen has entered an exclusive agreement with Chinese firm Simcere Pharmaceutical Group to co-develop and commercialise four biosimilars in China.